|
|
|
|
|
Neurodegenerative Disease Market Research Reports
|
| Alzheimer disease - new drugs, markets and companies |
|
| Table of Contents Published: Sep, 2010 Price: US $ 3200 Published by: Jain Pharmabiotech |
| Alzheimer' s disease remains a challenge in management. With nearly 8 million sufferers from this condition in the seven major markets of the world and anticipated increases in the future. Considerable research is in progress to understand the pathomechan ... |
| Neuroprotection - Drugs, Markets and Companies |
|
| Table of Contents Published: Sep, 2010 Price: US $ 4500 Published by: Jain Pharmabiotech |
| This report describes the role of neuroprotection in acute disorders such as stroke and injuries of the nervous system as well as in chronic diseases such as neurodegenerative disorders because many of the underlying mechanisms of damage to neural tissues ... |
| Multiple Sclerosis Market Forecast |
|
| Published: Jul, 2010 Price: US $ 15200 Published by: Datamonitor |
| With FDA advisory board support for Gilenia (fingolimod), Novartis will move ahead of Merck Serono' s oral cladribine in the race to become the first oral multiple sclerosis therapy. ... |
| Neurodegenerative Drugs |
|
| Table of Contents Published: Apr, 2010 Price: US $ 3950 Published by: Global Industry Analysts, Inc. |
| This report analyzes the worldwide markets for Neurodegenerative Drugs in US$ Million. ... |
| Huntington's Disease Therapeutics |
|
| Table of Contents Published: Apr, 2010 Price: US $ 3950 Published by: Global Industry Analysts, Inc. |
| This report analyzes the Global market forHuntington' s Disease Therapeutics in US$ Million. Annual estimates and forecasts are provided for the period 2009 through 2015. ... |
| Lou Gehrig's Disease |
|
| Table of Contents Published: Apr, 2010 Price: US $ 3450 Published by: Global Industry Analysts, Inc. |
| This report analyzes the Global market for Lou Gehrig' s Disease in US$ Million. Annual estimates and forecasts are provided for the period 2006 through 2015. ... |
| Licensing Opportunities: Neurology |
|
| Table of Contents Published: Apr, 2010 Price: US $ 2300 Published by: Decision Resources, Inc. |
| The future of drug discovery and development will be modeled on extensive cooperation and collaboration between multiple academic, government, nonprofit, and industry stakeholders - not on the individual R&D silos that pharmaceutical companies have instit ... |
| Biomarkers in Parkinson's Disease, 2010 |
|
| Table of Contents Published: Apr, 2010 Price: US $ 2333 Published by: BioPharm Reports (Technology and Markets Ltd) |
| This report presents a comprehensive update on PD biomarker developments up to April 2010. It covers the major classes of emerging and new markers relating to PD (blood, CSF, metabolomic, image-based, genetic and others), and focuses on those investigated ... |
| Global Multiple Sclerosis Drug Market 2010-2025 |
|
| Table of Contents Published: Mar, 2010 Price: US $ 2224 Published by: Visiongain |
| The multiple sclerosis (MS) treatments market is one of the largest for CNS disorders, with total pharmaceutical revenues of over $8bn in 2009. Revenues for MS treatments will rise significantly from 2010 to 2025, our new study reveals. ... |
| U.S. Markets for Neurostimulation Products |
|
| Table of Contents Published: Mar, 2010 Price: US $ 4750 Published by: Medtech Insight |
| One of the most promising medical device markets to date is neurostimulation. This newest report from Medtech Insight includes analyses of products, markets, competitors, and opportunities in the United States (U.S.) neurostimulation products market. ... |
| The CNS Market Outlook to 2014: Competitive landscape, pipeline analysis and growth opportunities |
|
| Table of Contents Published: Jan, 2010 Price: US $ 3835 Published by: Business Insights |
| The CNS disorders market may be segmented into numerous subcategories, including major depressive disorder (MDD), epilepsy, schizophrenia, Alzheimer' s disease (AD), Parkinson' s disease (PD), migraine, insomnia, attention-deficit hyperactivity disorder ( ... |
| Neuropathic Pain Market Forecast |
|
| Table of Contents Published: Dec, 2009 Price: US $ 15200 Published by: Datamonitor |
| Datamonitor forecasts the neuropathic pain market to more than double in value from 2008 to total $5.2 billion by 2018 across the seven major markets (US, Japan, and the 5EU (France, Germany, Italy, Spain and the UK)). ... |
| CNS Therapeutics - A World Market Review |
|
| Table of Contents Published: Nov, 2009 Price: US $ 2995 Published by: BizAcumen, Inc. |
| While the available CNS therapies can slow down deteriorating condition of patient, the clinical pipeline boasts of new drug classes with potential to stop or reverse the disease' s progression. Continuing switch over of patients from typical or tradition ... |
| Neurostimulation - A Global Market Perspective |
|
| Table of Contents Published: Nov, 2009 Price: US $ 2995 Published by: BizAcumen, Inc. |
| The world neurostimulation market stands enthused by the growing base of aging population, and the resultant rise in age-related diseases such as, Parkinson' s, and Alzheimer' s disease. Widespread prevalence of neurological disorders and conditions, and ... |
| Dealmaking and Industry Outlook: Neurological Disease |
|
| Table of Contents Published: Nov, 2009 Price: US $ 2300 Published by: Decision Resources, Inc. |
| The plethora of recent reports of new genes and pathways linked to neurological diseases shows that the underlying causes of these diseases are far from certain; as a result, therapeutic strategies in effect today may soon be superseded by new approaches. ... |
| Immunotherapies and Vaccines for Nontraditional Indications |
|
| Table of Contents Published: Oct, 2009 Price: US $ 2995 Published by: Insight Pharma Reports |
| This report: Covers a wide range of conditions for which immunotherapies may be effective, including Alzheimer' s disease, addiction, other neurological indications, cardiovascular diseases, hematological disorders, ophthalmic diseases, bone metabolism di ... |
| World Neurodegenerative Diseases Market 2009-2024 |
|
| Table of Contents Published: Sep, 2009 Price: US $ 2224 Published by: Visiongain |
| Rising neurodegenerative disease prevalence and expanding patent populations - where are the best opportunities and how can you unlock these? Our new report - World Neurodegenerative Diseases Market 2009-2024 - explains. ... |
| Chinese Markets for Central Nervous System Disorder Drugs |
|
| Table of Contents Published: Sep, 2009 Price: US $ 4000 Published by: Asia Market Information & Development Co. |
| China' s demand for Central Nervous System Disorder Drugs has grown at a fast pace in the past decade. In the next five years, both production and demand will continue to grow. This new study examines China' s economic trends, investment environment, indu ... |
| The Pricing and Reimbursement Environment for Neurology Drugs |
|
| Table of Contents Published: Aug, 2009 Price: US $ 2300 Published by: Decision Resources, Inc. |
| Neurological disorders will impose a growing social and fi nancial burden on the major pharmaceutical markets as the elderly population in these countries increases steadily. Governments and other payers recognize the pressing need to tackle these disease ... |
| Neurological Disease: Early-Stage R&D and Dealmaking |
|
| Table of Contents Published: Aug, 2009 Price: US $ 2300 Published by: Decision Resources, Inc. |
| How can early-stage R&D efforts be positioned to tap the remaining opportunity in the neurology drug market? Although brimming with potential, neurology drug development is also rife with unique challenges that many companies and agents have been unable t ... |
| The Neurology Pipeline: A Strategic Review |
|
| Table of Contents Published: Aug, 2009 Price: US $ 2300 Published by: Decision Resources, Inc. |
| Mega-blockbuster status would be quick and sure for any safe, effective agent that prevents the death and damage of neurons associated with neurodegenerative diseases. The potential of such a neuroprotectant is one of the motivations for the 188 companies ... |
| Levodopa (CAS 59-92-7) Market Report 2009 |
|
| Table of Contents Published: Jun, 2009 Price: US $ 2650 Published by: Merchant Research & Consulting LTD. |
| The study 'Levodopa (CAS 59-92-7) Market Report 2009' presents an overview of the Praduct market globally and regionally by contemplating and analyzing its parameters. ... |
| Fibromyalgia Market Forecast |
|
| Table of Contents Published: Jun, 2009 Price: US $ 15200 Published by: Datamonitor |
| Until regulatory hurdles in the EU are overcome, the US offers the greatest commercial potential and will be the primary growth market for all current and future brands indicated for fibromyalgia. Datamonitor forecasts the fibromyalgia market to more than ... |
| Chinese Markets for Alzheimer Disease Drugs |
|
| Table of Contents Published: Apr, 2009 Price: US $ 4000 Published by: Asia Market Information & Development Co. |
| China' s demand for Alzheimer Disease Drugs has grown at a fast pace in the past decade. In the next five years, both production and demand will continue to grow. This new study examines China' s economic trends, investment environment, industry developme ... |
| The Global Multiple Sclerosis Market 2009-2024 |
|
| Table of Contents Published: Mar, 2009 Price: US $ 2224 Published by: Visiongain |
| The multiple sclerosis (MS) market has total global revenues of over $6bn in 2008. Those revenues will exceed $9bn during the second half of next decade, our new study shows. The World Health Organization estimates that over 2.5 million people suffer from ... |
| Multiple Sclerosis Treatment Market: Opportunities for Oral Drugs |
|
| Table of Contents Published: Mar, 2009 Price: US $ 800 Published by: Koncept Analytics |
| This report analyses the global multiple sclerosis market demand and potential opportunities prevailing in the market. It gives an overview of the disease and prevalence worldwide, also covers the total market for MS treatment. It presents global MS injec ... |
| Global Alzheimer Drugs Market: An Analysis |
|
| Table of Contents Published: Mar, 2009 Price: US $ 700 Published by: Koncept Analytics |
| This report analyzes Alzheimer' s disease treatment and diagnosis market and discusses major drugs being used for the treatment of AD in United States, Japan and China. It analyses major growth drivers and opportunities present in the market. The report a ... |
| US Markets for Neurostimulation Devices 2009 |
|
| Table of Contents Published: Feb, 2009 Price: US $ 5495 Published by: Millennium Research Group |
| The US market for neurostimulation devices, which includes spinal cord, deep brain, sacral nerve, vagus nerve, and gastric stimulation devices was valued at over $1 billion in 2008. ... |
| Neurodegenerative Market Forecast to 2013 |
|
| Table of Contents Published: Feb, 2009 Price: US $ 6995 Published by: Cutting Edge Information |
| In one convenient, easy-to-access format, Neurodegenerative Market Forecast to 2013 provides a compelling, full picture of the Alzheimer' s, Multiple Sclerosis and Parkinson' s markets. ... |
| Sleep Disorders - US - November 2008 |
|
| Table of Contents Published: Nov, 2008 Price: US $ 3995 Published by: Mintel International Group Ltd, |
| The U.S. Sleep Aid market has doubled between 2002 and 2007. OTC and homeopathic segments, which are considerably smaller, are likely to continue growing, fueled by fears surrounding side effects and dependencies that may result from prescription solution ... |
| US Neuropathic Pain 2008, 4th Edition |
|
| Table of Contents Published: Sep, 2008 Price: US $ 7500 Published by: WWMR, Inc. |
| Neuropathic pain (NP) can have chronic, debilitating impact on the lives of patients with a variety of conditions, including low back pain, diabetes, herpes, trigeminal neuralgia, HIV/AIDS, neuropathic cancer pain and fibromyalgia. Many patients and their ... |
| CNS Drug Discoveries: what the future holds |
|
| Table of Contents Published: Aug, 2008 Price: US $ 1040 Published by: Espicom Business Intelligence |
| A comprehensive examination of 5 CNS therapy areas: multiple sclerosis, Parkinson' s disease, Alzheimer' s disease, schizophrenia and depression. The report includes unique market share and sales forecasts by product to 2014, as well as detailed competito ... |
| CNS Drug Discoveries: Parkinson's disease |
|
| Table of Contents Published: Aug, 2008 Price: US $ 1040 Published by: Espicom Business Intelligence |
| In 2007, approximately US$3.6 billion was spent on the symptomatic treatment of Parkinson' s disease (PD). Although this neurodegenerative disease affects approximately 1% of the population its prevalence increases with age, thus it is likely to become mo ... |
| CNS Drug Discoveries: Alzheimer's Disease |
|
| Table of Contents Published: Aug, 2008 Price: US $ 1040 Published by: Espicom Business Intelligence |
| Espicom' s best-selling CNS Drug Discoveries: what the future holds provides a comprehensive examination of 5 major CNS therapy areas: multiple sclerosis, Alzheimer' s disease, Parkinson' s disease, schizophrenia and depression. The information below and ... |
| CNS Biomarkers Players, products and prospects |
|
| Table of Contents Published: Aug, 2008 Price: US $ 1040 Published by: Espicom Business Intelligence |
| The CNS biomarker market represents one of the smallest segments of biomarkers in terms of revenue as relatively few CNS biomarkers are commercially available. In 2007, we estimate the CNS biomarker market accounted for less than 5% of biomarker revenues, ... |
| Brands & Strategies: Alzheimer's Disease |
|
| Table of Contents Published: Jun, 2008 Price: US $ 13875 Published by: Decision Resources, Inc. |
| In 2007, the Alzheimer' s disease (AD) market, valued at more than $3 billion in the United States, Europe, and Japan, was led by sales of Eisai/Pfizer' s Aricept. The growth of all the currently available agents will decline by the end of our forecast, a ... |
| CNS Therapeutics |
|
| Table of Contents Published: May, 2008 Price: US $ 3950 Published by: Global Industry Analysts, Inc. |
| This report analyzes the worldwide markets for CNS Therapeutics in Millions of US$. The specific product Groups analyzed are Anti-Alzheimer' s, Anti-Parkinson' s, Anti-Epilepsy, Pain Management (includes Migraine, Nociceptive and neuropathic pain), Anti-P ... |
| Alzheimer's and Parkinson's Disease |
|
| Table of Contents Published: May, 2008 Price: US $ 3950 Published by: Global Industry Analysts, Inc. |
| This report analyzes the worldwide markets for Alzheimer' s and Parkinson' s Disease in Millions of US$. The Major product segments Analyzed are Anti-Alzheimer' s Disease Drugs (Cholinesterase Inhibitors, & NMDARA), and Anti-Parkinson' s Disease Drugs (Do ... |
| CNS Generic Drugs: Prospects and Opportunities to 2012 |
|
| Table of Contents Published: Apr, 2008 Price: US $ 1890 Published by: Espicom Business Intelligence |
| This important new strategic report from Espicom evaluates the CNS generic drug market and provides detailed assessment and forecast for leading products by value to 2012, patent expiry opportunities to 2015 and competitive evaluation. ... |
| Emerging Drug Targets in Alzheimer's Disease |
|
| Table of Contents Published: Dec, 2007 Price: US $ 1669 Published by: Decision Resources, Inc. |
| The lack of effective treatments for Alzheimer' s disease (AD) and an aging population create an enormous opportunity for disease-modifying drugs. Competition to develop new drugs for AD is in fact fi erce, and the effi cacy bar for current AD therapies i ... |
| Africa and Middle East Media Forecast |
|
| Price: Contact Us Published by: Pyramid Research, Inc. |
| The following list of definitions has been developed by Pyramid Research to help our clients better understand the data and market analysis presented in our services and reports. It represents an ongoing process in which we continually assess and reevalua ... |
| CNS Drug News |
|
| Issues / Year: 22 Price: US $ 1035 Published by: Espicom Business Intelligence |
| "An exciting business intelligence service designed to keep you in touch with the latest developments in the central nervous system drug market ... |
| Neuro Drug Focus (NDF) |
|
| Issues / Year: 12 Price: US $ 1065 Published by: Espicom Business Intelligence |
| Neuro Drug Focus (NDF) is a new business news service that will keep you fully updated with the latest developments in neurodegenerative product registration, agreements and clinical trials. ... |
|
|
View Cart
